TFC 039
Alternative Names: SBM TFC 039; TFC-039; Wangeliejin; WanpagliflozinLatest Information Update: 28 Jun 2024
At a glance
- Originator Sirona Biochem
- Developer Sirona Biochem; Wanbang Biopharma
- Class Antihyperglycaemics; Carbohydrates; Obesity therapies
- Mechanism of Action Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Diabetes mellitus
Highest Development Phases
- Research Unspecified
- No development reported Obesity; Type 2 diabetes mellitus
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in China (PO)
- 20 Jun 2022 Phase-I development is ongoing for Type 2 diabetes mellitus in China (PO) (Sirona Biochem pipeline, June 2022)
- 13 Dec 2021 Early research in Unspecified in Canada (PO)